NASDAQ:CYAD
Delisted
Celyad SA Stock News
$0.470
+0 (+0%)
At Close: Aug 17, 2023
MONT-SAINT-GUIBERT, Belgium, July 20, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD) (Celyad Oncology or the Company), a clinical-stage biotechnology company focused on the disc
Celyad Oncology to Participate at the William Blair Biotech Focus Conference 2021
04:01pm, Wednesday, 07'th Jul 2021
MONT-SAINT-GUIBERT, Belgium, July 07, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric
MONT-SAINT-GUIBERT, Belgium, June 11, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric
Celyad Oncology Announces June 2021 Conference Schedule
01:00am, Wednesday, 26'th May 2021
MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Regulatory News: Celyad Oncology SA (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused o
Transparency notification received from Victory Capital Management Inc. (Article 14 §1 of the Law of 2 May 2007)
01:00am, Wednesday, 19'th May 2021
MONT-SAINT-GUIBERT, Belgium, May 19, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric
Celyad Oncology (CYAD) Stock: Over 20% Increase Pre-Market Explanation
06:53am, Thursday, 13'th May 2021
The stock price of Celyad Oncology (NASDAQ: CYAD) increased by over 20% pre-market. This is why it happened.
Transparency Notification Received from Tolefi SA (Article 14 §1 of the Law of 2 May 2007)
01:00am, Wednesday, 05'th May 2021
MONT-SAINT-GUIBERT, Belgium, May 05, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric
Celyad Oncology Appoints Dr. Charles Morris as Chief Medical Officer
01:00am, Monday, 19'th Apr 2021
MONT-SAINT-GUIBERT, Belgium, April 19, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeri
Celyad Oncology Announces April 2021 Conference Schedule
01:00am, Thursday, 01'st Apr 2021
MONT-SAINT-GUIBERT, Belgium, April 01, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeri
Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)
01:00am, Wednesday, 31'st Mar 2021
MONT-SAINT-GUIBERT, Belgium, March 31, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeri
Celyad Oncology's (CYAD) CEO Filippo Petti on Q4 2020 Results - Earnings Call Transcript
02:52am, Friday, 26'th Mar 2021
Celyad Oncology's (CYAD) CEO Filippo Petti on Q4 2020 Results - Earnings Call Transcript
Celyad Oncology Reports Full Year 2020 Financial Results and Recent Business Highlights
04:01pm, Wednesday, 24'th Mar 2021
MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Regulatory News: Celyad Oncology SA (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused o
Celyad Oncology to Announce Full Year 2020 Financial Results and Host Conference Call
02:00am, Thursday, 18'th Mar 2021
MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Regulatory News: Celyad Oncology SA (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused o
Celyad Oncology Announces March 2021 Conference Schedule
04:01pm, Monday, 01'st Mar 2021
MONT-SAINT-GUIBERT, Belgium, March 01, 2021 (GLOBE NEWSWIRE) -- Mont-Saint-Guibert, Belgium – Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the disc
Celyad Oncology Announces February 2021 Conference Schedule
01:00am, Tuesday, 02'nd Feb 2021
MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Regulatory News: Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric
